Suchergebnisse - "Sun, Chaoyang"

PubPharm (8)

1

Codelivery of adavosertib and olaparib by tumor-targeting nanoparticles for augmented efficacy and reduced toxicity

enthalten in: Acta biomaterialia | 2023

von Wang, W. | Xiong, Y. | Hu, X. | +14

2

Mutation profiles in circulating cell-free DNA predict acquired resistance to olaparib in high-grade serous ovarian carcinoma

enthalten in: Cancer science | 2022

von Hu, D. | Guo, E. | Yang, B. | +18

3

MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors

enthalten in: Cancer research | 2021

von Yang, B. | Li, X. | Fu, Y. | +14

4

Systems approach to rational combination therapy : PARP inhibitors

enthalten in: Biochemical Society transactions | 2020

von Sun, C. | Fang, Y. | Labrie, M. | +2

5

Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy

enthalten in: Cancer cell | 2019

von Fang, Y. | McGrail, D. | Sun, C. | +24

CommentIn: Cancer Cell. 2019 Jun 10;35(6):821-822. - PMID 31185206

6

BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency

enthalten in: Cancer cell | 2018

von Sun, C. | Yin, J. | Fang, Y. | +17

7

Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers

enthalten in: Science translational medicine | 2017

von Sun, C. | Fang, Y. | Yin, J. | +17

ErratumIn: Sci Transl Med. 2024 Mar 20;16(739):eadp0392. - PMID 38507471

8

miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition

enthalten in: Journal of the National Cancer Institute | 2013

von Sun, C. | Li, N. | Yang, Z. | +10

1
[1]